Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

PRLD
Prelude Therapeutics Incorporated
stock NASDAQ

At Close
Feb 20, 2026 3:59:56 PM EST
2.79USD+22.907%(+0.52)832,147
0.00Bid   0.00Ask   0.00Spread
Pre-market
Feb 20, 2026 8:07:30 AM EST
2.15USD-5.286%(-0.12)580
After-hours
Feb 20, 2026 4:50:30 PM EST
2.76USD-1.075%(-0.03)32,229
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 11, 2022
06:44AM EST  Prelude Therapeutics Granted U.S. Patent #11,220,524 'Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)'   Benzinga
Jan 5, 2022
11:07AM EST  Stocks That Hit 52-Week Lows On Wednesday   Benzinga
Jan 4, 2022
07:00AM EST  Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present at the H.C Wainwright BioConnect Virtual Conference, being held on January 10-13, 2022.   GlobeNewswire Inc
Dec 20, 2021
09:47AM EST  5 Value Stocks In The Healthcare Sector   Benzinga
Nov 23, 2021
07:00AM EST  Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference taking place on Wednesday, December 1, 2021 at 9:15 am ET.   GlobeNewswire Inc
Nov 17, 2021
08:29AM EST  Barclays Maintains Overweight on Prelude Therapeutics, Lowers Price Target to $20   Benzinga
Nov 12, 2021
08:07AM EST  Prelude Therapeutics Q3 EPS $(0.66) Up From $(5.25) YoY   Benzinga
08:00AM EST  PRT543 and PRT811 Demonstrate Favorable Safety Profile, Tolerability and Evidence of Preliminary Clinical Activity in Phase 1 Dose Escalation in Unselected Patients   GlobeNewswire Inc
Nov 8, 2021
09:05AM EST  Prelude Therapeutics Announces IND Clearance For PRT2527, A Highly Selective CDK9 Inhibitor   Benzinga
09:00AM EST  Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for its precision oncology candidate, PRT2527, which is designed to be a potent and selective CDK9 inhibitor.   GlobeNewswire Inc
Oct 12, 2021
10:06AM EDT  Prelude Therapeutics Reports Will Collab With DarwinHealth To Develop Novel Biomarkers For Multiple Oncology Candidates   Benzinga
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Oct 11, 2021
11:14AM EDT  Morgan Stanley Upgrades Prelude Therapeutics to Overweight, Lowers Price Target to $35   Benzinga
Oct 10, 2021
11:59AM EDT  The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations and IPOs Take Center Stage   Benzinga
Oct 8, 2021
09:06AM EDT  Barclays Maintains Overweight on Prelude Therapeutics, Lowers Price Target to $33   Benzinga
Oct 7, 2021
03:12PM EDT  Mid-Afternoon Market Update: Crude Oil Rises 1%; New Fortress Energy Shares Spike Higher   Benzinga
12:28PM EDT  Mid-Day Market Update: Dow Jumps Over 500 Points; Osmotica Pharmaceuticals Shares Slide   Benzinga
10:44AM EDT  Mid-Morning Market Update: Markets Open Higher; Conagra Brands Profit Beats Views   Benzinga
09:15AM EDT  Prelude Therapeutics Announces Presentation Of Data From Multiple Programs At AACR-NCI-EORTC Virtual International Conference   Benzinga
09:00AM EDT  Lead oral PRMT5 inhibitors PRT543 and PRT811 demonstrate favorable safety profile, evidence of preliminary clinical activity including durable responses and high levels of target inhibition of PRMT5 in Phase 1 dose escalation in unselected patients   GlobeNewswire Inc
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 3, 2021
02:21PM EDT  The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs and More   Benzinga
Sep 2, 2021
07:00AM EDT  Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences:   GlobeNewswire Inc
Aug 12, 2021
07:59AM EDT  Prelude Therapeutics Q2 Net Loss $26.9 Mln Or $0.58/Shr Vs Loss Of $11.4 Mln Or $5.50/Shr Last Year   RTTNews
07:42AM EDT  Prelude Therapeutics Q2 EPS $(0.58) Up From $(5.50) YoY   Benzinga
07:30AM EDT  - Data from Dose Escalation Portion of Phase 1 Trials of Lead Oral PRMT5 InhibitorsPRT543 and PRT811 to be Presented in 4Q21   GlobeNewswire Inc
Jul 27, 2021
12:32PM EDT  Why BofA Is Turning Bullish On Prelude Therapeutics   Benzinga
11:13AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2021   Benzinga
11:13AM EDT  B of A Securities Upgrades Prelude Therapeutics to Buy, Announces $60 Price Target   Benzinga
Jul 19, 2021
07:13AM EDT  Prelude Therapeutics Appoints Martin Babler To Its Board   RTTNews
07:00AM EDT  Prelude Therapeutics Announces Appointment of Martin Babler to its   GlobeNewswire Inc
Jun 2, 2021
07:00AM EDT  Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences:   GlobeNewswire Inc
May 11, 2021
07:57AM EDT  Prelude Therapeutics Q1 EPS $(0.47)   Benzinga
07:30AM EDT  - Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhibitor PRT543 -   GlobeNewswire Inc
May 5, 2021
07:00AM EDT  Prelude Therapeutics Inc. (Prelude, the Company, we, our) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present at the BofA Securities 2021 Virtual Health Care Conference on Wednesday, May 12 at 5:00 p.m. ET.   GlobeNewswire Inc
Apr 26, 2021
10:06AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 26, 2021   Benzinga
06:30AM EDT  HC Wainwright & Co. Initiates Coverage On Prelude Therapeutics with Buy Rating, Announces Price Target of $62   Benzinga
Mar 17, 2021
07:39AM EDT  Morgan Stanley Maintains Equal-Weight on Prelude Therapeutics, Raises Price Target to $60   Benzinga
Mar 16, 2021
08:25AM EDT  Prelude Therapeutics Q4 EPS $(0.45)   Benzinga
08:00AM EDT  Dose Escalation Portion of Phase 1 Trial of PRT543 Complete; Additional Expansion Cohorts Set to Initiate Early in the Second Quarter   GlobeNewswire Inc
Mar 3, 2021
07:00AM EST  Prelude Therapeutics Inc. (Prelude, the Company, we, our) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in three upcoming virtual investor conferences:   GlobeNewswire Inc
Feb 10, 2021
07:34AM EST  The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs   Benzinga
Jan 11, 2021
06:20PM EST  Prelude Therapeutics Announces Closing of Upsized Public Offering   GlobeNewswire Inc
Jan 7, 2021
05:47AM EST  Prelude Therapeutics Priced 2.2M Share Upsized Public Offering @$60/Share   Benzinga
12:23AM EST  Prelude Therapeutics Announces Pricing Of Upsized Public Offering At $60/Shr   RTTNews
12:13AM EST  Prelude Therapeutics Announces Pricing of Upsized Public Offering   GlobeNewswire Inc
Jan 5, 2021
08:39AM EST  The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data   Benzinga
Jan 4, 2021
04:17PM EST  Prelude Therapeutics Announces Launch of Proposed Public Offering   GlobeNewswire Inc
04:12PM EST  Prelude Therapeutics S-1 Shows Registration For 1.75M Common Stock Offering   Benzinga
Dec 23, 2020
08:31AM EST  The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut   Benzinga
Dec 18, 2020
07:48AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data   Benzinga
07:45AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data   Benzinga
Dec 16, 2020
01:05PM EST  Morgan Stanley Maintains Equal-Weight on Prelude Therapeutics, Raises Price Target to $47   Benzinga
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 11, 2020
08:11AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street   Benzinga
Nov 12, 2020
08:08AM EST  Morgan Stanley Maintains Equal-Weight on Prelude Therapeutics, Raises Price Target to $38   Benzinga
Nov 10, 2020
07:35AM EST  Prelude Therapeutics Q3 EPS $(5.25) Down From $(3.93) YoY   Benzinga
07:30AM EST  - CompletedInitial Public Offering of Common Stock, Raising Gross Proceeds of ~$181.9M-   GlobeNewswire Inc
Oct 20, 2020
07:48AM EDT  B of A Securities Initiates Coverage On Prelude Therapeutics with Buy Rating, Announces Price Target of $40   Benzinga
06:42AM EDT  Goldman Sachs Initiates Coverage On Prelude Therapeutics with Neutral Rating, Announces Price Target of $37   Benzinga
06:40AM EDT  Morgan Stanley Initiates Coverage On Prelude Therapeutics with Equal-Weight Rating   Benzinga
Sep 30, 2020
05:45PM EDT  Baker Bros. Advisors In 13D Filing Shows 31.1% Stake In Prelude Therapeutics   Benzinga
07:14AM EDT  Prelude Therapeutics Announces Dosing of First Patient in Phase 1 Trial of MCL1 Inhibitor PRT1419 for the Treatment of Relapsed/Refractory Hematologic Malignancies   Benzinga
07:09AM EDT  Prelude Therapeutics Doses First Patient In Phase 1 Trial Of MCL1 Inhibitor PRT1419 For R/r Hematologic Malignancies   RTTNews
07:00AM EDT  Prelude Therapeutics Announces Dosing of First Patient in Phase 1   GlobeNewswire Inc
Sep 29, 2020
04:05PM EDT  Prelude Therapeutics Announces Closing of Initial Public Offering   GlobeNewswire Inc
Sep 25, 2020
03:07PM EDT  Mid-Afternoon Market Update: Dow Jumps Over 300 Points; Standard AVB Financial Shares Climb   Benzinga
11:44AM EDT  Prelude Therapeutics Shares Open For Trade At $25.23; IPO Priced At $19/Share   Benzinga
11:30AM EDT  Prelude Therapeutics Shares Indicating $25.01 On 333K Shares   Benzinga
11:07AM EDT  Prelude Therapeutics Shares Indicated $21.14   Benzinga
10:18AM EDT  IPOs Expected Today: Graybug Vision; Prelude Therapeutics; Amesite Inc.; PMV Pharmaceuticals; Greenwich LifeSciences; Siyata Mobile; Vector Acquisition Corporation; Fintech Acquisition Corp IV   Benzinga
09:37AM EDT  Prelude Therapeutics Shares Expected To Open For Quote At 10:35 a.m. Expected To Open For Trade After 10:45 a.m. EDT; IPO Priced At $19/Share   Benzinga
05:42AM EDT  Prelude Therapeutics Prices 8.325M Share IPO @$19/Share   Benzinga
Sep 24, 2020
08:50PM EDT  Prelude Therapeutics Announces Pricing of Initial Public Offering   GlobeNewswire Inc
08:05AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Thursday, Sept. 24, 2020: MU, PRLD, PECK, SOLO, NKLA   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC